Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. I'm talking about (NASDAQ: NVAX) and Ocugen (NASDAQ: OCGN). Both companies raced to bring a coronavirus vaccine to market.

As it turns out, Novavax reached commercialization -- but later than today's market leaders, Pfizer and Moderna. And Ocugen dropped its flagship vaccine program and replaced it with earlier-stage work on inhaled-vaccine candidates.

Both stocks are falling in the double digits this year, and that's after poor performance last year. But could they be heading for a major rebound as Wall Street predicts? And should you get in on these recovery stories?

Continue reading

Source Fool.com